Key result
Vitamin-K antagonists were prescribed to 61% of elderly patients with atrial fibrillation, with rates of 65% in those with very high stroke risk versus 55% in those with high risk (P=0.065).
Observational (n=342)
Yes
Absolute Event Rate: 65% vs 55%
p-value: p=0.065
In a Greek registry of elderly patients with atrial fibrillation, VKA prescription was primarily driven by stroke risk rather than being deterred by bleeding risk.
Stroke risk drove VKA decisions in elderly AF; leaves open whether bleeding concerns or NOAC availability now alter real-world uptake.
BACKGROUND: Patients with atrial fibrillation aged 75 years or older have a CHA2DS2VASc score that dictates oral anticoagulants. We recorded physicians' anticoagulation attitudes in elderly patients with atrial fibrillation and assessed the impact of stroke and bleeding risk. METHODS: Atrial Fibrillation To Investigate the Implementation of New Guidelines , a countrywide prospective registry performed in Greece during 2010, a period when only vitamin-K antagonists (VKA) were available, enrolled 1127 patients with atrial fibrillation diagnosis during Emergency Departments visit in 31 representative hospitals; 807 patients had known atrial fibrillation and of those, 342 aged 75 years or older. We recorded preadmission anticoagulation treatment and associated it with clinical characteristics and stroke/bleeding risk. RESULTS: Patients on VKA (n = 207; 61%) were younger (81 ± 4 vs. 83 ± 5; P < 0.001) but no other significant differences were noticed, including mean CHA2DS2VASc (high: 2-4, very high: >4) or modified HASBLED (low: 0-2, high: >2) scores. VKA were prescribed in 65% of patients with very high CHA2DS2VASc score as compared with 55% of those with high score (P = 0.065). VKA were used equally in low or high-modified HASBLED score (61% vs. 59%; P = 0.78). The interaction between CHA2DS2VASc and HASBLED was significant (P < 0.001) in patients on VKA; in patients with low HASBLED, VKA use was similar in high versus very high CHA2DS2VASc score (58 vs. 64%), whereas in patients with high HASBLED, VKA use tended to be higher in very high versus high CHA2DS2VASc score (66 vs. 43%). CONCLUSION: In this countrywide atrial fibrillation registry, 61% of elderly patients received VKA, a decision driven mainly by stroke risk. VKA use was not higher in patients with low bleeding risk.
No takes yet. Share an insight, caveat, or question.
Pipilis et al. (2016) conducted an observational in Atrial fibrillation (n=342). Vitamin-K antagonists (VKA) vs. No VKA was evaluated on VKA prescription in very high vs high CHA2DS2VASc score (p=0.065). Vitamin-K antagonists were prescribed to 61% of elderly patients with atrial fibrillation, with rates of 65% in those with very high stroke risk versus 55% in those with high risk (P=0.065).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: